prostate
Sanofi prostate cancer drug to remain on CDF
May 26, 2015Sales and Marketing CDF, Cancer, NHS, Sanofi, list, prostate
Sanofi has reached an agreement with NHS England to reinstate its prostate cancer drug Jevtana on the Cancer Drugs Fund. …
More cancer patients surviving for longer
October 31, 2014Medical Communications, Research and Development, Sales and Marketing Cancer, bladder, breast, myeloma, oncology, ons, prostate
Cancer survival rates in England are continuing to improve, though many cancers still have an ‘extremely poor’ prognosis, according to …
FDA approves new indication for Xtandi
September 11, 2014Sales and Marketing Astellas, FDA, Medivation, Xtandi, Zytiga, prostate
The FDA has approved Astellas Pharma and Medivation’s prostate cancer drug Xtandi (enzalutamide) for use in patients who have not …
Top four cancer killer rates ‘fall by a third’
August 18, 2014Research and Development, Sales and Marketing CRUK, Cancer, bowel, charity, lung, prostate, research
Death rates for breast, bowel, lung and prostate cancer combined have fallen by almost a third in the last 20 …
Charities ‘disappointed’ in NICE and Janssen
August 15, 2014Sales and Marketing Cancer, Janssen, NHS, NICE, Zytiga, prostate
The Institute of Cancer Research and Prostate Cancer UK are both urging NICE and Janssen to ‘get their act together’ …
Dendreon chief resigns from struggling firm
June 10, 2014Medical Communications, Sales and Marketing Cancer, Dendreon, John Johnson, Provenge, Vaccine, Watson, prostate
Chief executive of Dendreon John Johnson is to step down in the summer amid falling sales of the company’s key …
NICE: no early Zytiga use
May 14, 2014Sales and Marketing Cancer, Janssen, NHS, NICE, Zytiga, johnson, prostate
Janssen has criticised NICE’s decision not to recommend Zytiga on the NHS at an earlier stage in the prostate cancer …
NICE recommends Xtandi
May 9, 2014Sales and Marketing Astellas, NICE, Xtandi, abiraterone, prostate
NICE has reiterated that Astellas Pharma’s Xtandi should be used to treat NHS prostate cancer patients – but has removed …
NICE says ‘no’ to Xofigo
March 24, 2014Sales and Marketing Bayer, CDF, NHS, NICE, abiraterone, prostate, xofigo
NICE has dealt Bayer a severe blow by not approving prostate cancer drug Xofigo for use on the NHS in …
Sir Michael Parkinson criticises NICE
February 4, 2014Medical Communications, Sales and Marketing Astellas, NHS, NICE, Xtandi, parkinson, prostate
TV host Sir Michael Parkinson has told NICE that it must lift the restrictions imposed on Astellas’ new prostate cancer …
Roche signs $17 million immatics deal
November 15, 2013Research and Development, Sales and Marketing Cancer, Roche, immatics, lung, prostate
Roche is to pay German biotech company immatics $17 million to collaborate on the search for vaccines in various cancers, …
Lilly UK sponsors ‘Go Dad Run’ charity
June 6, 2013Medical Communications go dad run, lilly, prostate
Lilly is sponsoring Olympic hurdler Colin Jackson’s ‘Go Dad Run’, a new 5k run for men to raise awareness of …
Patients ‘shut out’ of drug price talks
November 13, 2012Sales and Marketing Cancer, NHS, NICE, VBP, prostate
Patients are being excluded from the negotiations between government and the pharma industry on the introduction of Value-Based Pricing (VBP).That …
AstraZeneca launches prostate cancer app
August 7, 2012Medical Communications AZ, AstraZeneca, PSA, Zoladex, diabetes, prostate
AstraZeneca has launched a new app that helps prostate cancer patients to monitor their PSA levels. It is not the …
Janssen looks to broaden Zytiga licence
June 18, 2012Sales and Marketing Cancer, Janssen, NICE, Provenge, Zytiga, prostate
Janssen is looking to broaden the licence for its prostate cancer pill Zytiga. Zytiga currently has a US and European …
